Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    0.00 (0.00%)
Bid:
143.00
Ask:
145.00
Spread: 2.00 (1.399%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading Statement

19 Jan 2012 07:00

RNS Number : 8017V
Xaar PLC
19 January 2012
 



 

 

 

FOR IMMEDIATE RELEASE

19 January 2012

 

 

 

Xaar plc

 

 

YEAR END TRADING UPDATE

 

 

Xaar plc ("Xaar" or "the Group" or "the Company"), the inkjet printing technology group headquartered in Cambridge, announces an update on trading for the year ended 31 December 2011.

 

Trading for the fourth quarter of the year was slightly ahead of the Board's expectations, leading to a strong performance for the full year 2011.

 

Xaar expects to announce revenue of approximately £69 million for 2011, an increase of over 25% compared to 2010 (£54.7 million).

 

Revenue growth in 2011 was achieved mainly by increased sales into the industrial segment. Demand for Xaar's technology in this segment is principally driven by the conversion of ceramic tile printing to digital inkjet from analogue processes. During the year, Xaar made good progress with the capacity expansion programme to support this demand and the programme remains on track to continue to deliver the planned incremental capacity during the first half of 2012.

 

As expected, product sales into the graphic arts segment declined in 2011 by approximately 15% compared to 2010. As previously described, this decline reflects market maturity and competitive pressure.

 

The Group continues to maintain a strong balance sheet with net cash at 31 December 2011 of £17.4 million (30 June 2011 - £20.6 million; 31 December 2010 - £22.0 million).

 

The detailed results for 2011 are expected to be announced on 20 March 2012.

 

Board changes

 

As previously announced Phil Eaves, Sales and Marketing Director, informed the Company in 2011 of his intention to retire from full time employment in June 2012. Following an extensive search process, the Company is pleased to announce that Richard Barham has been appointed Sales and Marketing Director and member of the Xaar board with effect from 5 March 2012. After completion of a handover period, Phil Eaves will continue to support the Company in a consultant role until 30 June 2012.

 

Ian Dinwoodie, Chief Executive commented:

 

'On behalf of everyone at Xaar, I would like to thank Phil for his efforts and contribution over the last 7 years during which our revenues have grown significantly. We all wish him well for the future.

 

I am pleased to welcome Richard to the Board, who brings a wealth of experience gained through 25 years spent in numerous sectors of the Imaging and Printing industries.'

Since 1986, Mr Barham has held a range of sales, marketing and management positions at Agfa Graphics NV, where most recently, since February 2008, he acted as Vice President of the Inkjet Division where he was responsible for turning the business around and integrating a major acquisition.

 

There is no further information concerning Mr Barham which requires disclosure under rule 9.6.13 of the UK Listing Authority Listing Rules.

 

 

END

 

CONTACTS

 

Xaar plc:

01223-423663

Ian Dinwoodie, Chief Executive

www.xaar.com

Alex Bevis, Finance Director

Singer Capital Markets Limited:

020-3205-7500

Shaun Dobson

Bankside Consultants:

Simon Bloomfield

020-7367-8888 / 07771-758517

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDVLFFLFFFBBB
Date   Source Headline
2nd Jun 202612:58 pmRNSTotal Voting Rights
28th May 20269:18 amRNSResult of AGM
6th May 20267:00 amRNSDirector/PDMR Shareholding
5th May 202611:36 amRNSHolding(s) in Company
30th Apr 20264:44 pmRNSHolding(s) in Company
16th Apr 20269:00 amRNSPublication of Annual Report and Notice of AGM
1st Apr 20263:43 pmRNSHolding(s) in Company
24th Mar 20267:05 amRNSFinal Results
23rd Mar 20263:33 pmRNS-RInvestor Presentation via Investor Meet Company
2nd Mar 20262:44 pmRNSTotal Voting Rights
14th Jan 20267:00 amRNSTrading Statement
5th Jan 202612:28 pmRNSTotal Voting Rights
5th Dec 20251:15 pmRNSHolding(s) in Company
1st Dec 202512:15 pmRNSTotal Voting Rights
24th Nov 202511:00 amRNSDirector/PDMR Shareholding
3rd Nov 20252:00 pmRNSTotal Voting Rights
21st Oct 20254:15 pmRNSDirector/PDMR Shareholding
13th Oct 20253:20 pmRNSHolding(s) in Company
2nd Oct 202511:10 amRNSDirector/PDMR Shareholding
2nd Oct 20258:50 amRNSDirector/PDMR Shareholding
1st Oct 20255:00 pmRNSDirector/PDMR Shareholding
1st Oct 20253:30 pmRNSTotal Voting Rights
1st Oct 202512:04 pmRNSTRADING UPDATE and NOTICE OF RESULTS
1st Sep 20254:30 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNS2025 INTERIM RESULTS
5th Aug 20257:00 amRNSBoard changes
1st Aug 20253:45 pmRNSTotal Voting Rights
14th Jul 202510:00 amRNSNotice of Interim Results
7th Jul 20253:30 pmRNSBlock listing Interim Review
2nd Jul 20253:30 pmRNSTotal Voting Rights
30th Jun 20252:00 pmRNSDirector/PDMR Shareholding
3rd Jun 202510:00 amRNSTotal Voting Rights
28th May 20253:30 pmRNSResult of AGM
21st May 20251:00 pmRNSHolding(s) in Company
7th May 20253:30 pmRNSNotification of Transactions of Directors & PDMRs
2nd May 202510:30 amRNSTotal Voting Rights
15th Apr 20251:15 pmRNS2024 Annual Report and Notice of AGM
11th Apr 202512:00 pmRNSHolding(s) in Company
1st Apr 20254:15 pmRNSHolding(s) in Company
1st Apr 20253:30 pmRNSTotal Voting Rights
31st Mar 20253:45 pmRNSNotification of Transactions of Directors & PDMRs
31st Mar 20251:10 pmRNSHolding(s) in Company
28th Mar 202511:30 amRNSHolding(s) in Company
27th Mar 202511:00 amRNSHolding(s) in Company
25th Mar 20255:00 pmRNSNotification of Transactions of Directors & PDMRs
25th Mar 20257:00 amRNSFinal Results
5th Mar 202511:30 amRNSTotal Voting Rights
19th Feb 202510:30 amRNSHolding(s) in Company
10th Feb 202511:00 amRNSHolding(s) in Company
5th Feb 20254:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.